Search
The Kids cancer researcher & clinician Dr Nick Gottardo has been announced as the recipient of an Innovation Grant from the Cure Brain Cancer Foundation.
A The Kids Research Institute Australia researcher will investigate new ways to harness the body’s own immune system to fight melanoma, thanks to Cancer Council WA funding.
Rennae's son Samuel was diagnosed with stage 4 neuroblastoma 13 years ago, and was originally given a 20% chance of survival. She bravely shares their story.
The WA Kids Cancer Centre has a suite of world-leading research projects to unlock new treatments for childhood cancers.
Associate Professor Lesterhuis said the gel, developed with the help of chemists at The University of Western Australia, could revolutionise the way solid tumours were treated.
Join us as WA’s cancer research community comes together at the inaugural West Coast Cancer Meeting.
The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTKs) consists of EGFR, ErbB2, ErbB3, and ErbB4. These receptors play key roles in cell proliferation, angiogenesis, cell migration, and in some cases, tumor promotion.
Antibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA‐4) and the programmed cell death protein 1/ligand 1 (PD-1/PD-L1) are now a treatment option for multiple cancer types. However, as a monotherapy, objective responses only occur in a minority of patients. Chemotherapy is widely used in combination with immune checkpoint blockade (ICB). Although a variety of isolated immunostimulatory effects have been reported for several classes of chemotherapeutics, it is unclear which chemotherapeutics provide the most benefit when combined with ICB.
With immune checkpoint therapy (ICT) having reshaped the treatment of many cancers, the next frontier is to identify and develop novel combination therapies to improve efficacy. Previously, we and others identified beneficial immunological effects of the vitamin A derivative tretinoin on anti-tumour immunity.
Cancer vaccination drives the generation of anti-tumor T cell immunity and can be enhanced by the inclusion of effective immune adjuvants such as type I interferons (IFNs). Whilst type I IFNs have been shown to promote cross-priming of T cells, the role of individual subtypes remains unclear. Here we systematically compared the capacity of distinct type I IFN subtypes to enhance T cell responses to a whole-cell vaccination strategy in a pre-clinical murine model.